Thursday, April 25, 2024 4/25/2024

Defining the Mechanism of Altered Very Long Chain Fatty Acid Metabolism in Neuro-Ichthyotic Disorders.

Award Number: R21AR076035
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Mutations in the Elongation of Very Long Chain Fatty Acids-4 (ELOVL4) gene cause neuro-ichthyotic disorder characterized by dry scaly skin (ichthyosis) and cognitive deficits, seizures and age-related cerebellar degeneration. ELOVL4 is an essential enzyme that mediates biosynthesis of very long chain (=C28) saturated (VLC-SFA) and polyunsaturated fatty acids (VLC-PUFA) that are collectively called very long chain fatty acids (VLC-FA). ELOVL4 is expressed in specific tissues in which it exhibits tissue-specific selectivity towards VLC- SFA and/or VLC-PUFA biosynthesis. In the skin, brain and Meibomian glands, ELOVL4 makes mainly VLC- SFA, while in the retina and testes it makes VLC-PUFA. However, the mechanisms by which one tissue makes VLC-SFA and the other VLC-PUFA, and how these VLC-FA exert their important protective roles in each tissue, remain unknown. Considering the fact that mutations in ELOVL4 affect skin and neuronal tissues, the answer must be in either the innate enzyme activity of the different mutant proteins or in a dominant negative effect of the mutant proteins on the quality and quantity of VLC-FA synthesized by the WT enzyme. The objective of this proposal is to examine what factors determine the tissue-specific selectivity of VLC-SFA biosynthesis relative to VLC-PUFA and how mutant ELOVL4 alters such factors to cause the different tissue- specific disorders. To achieve his goal, we generated the first Long Evans rat model of ELOVL4 mutation (c.736T>G, p.W246G) that causes Spinocerebellar ataxia 34 (SCA34) with Erythrokeratodermia variabilis (EKV). Compared to wild type control rats, heterozygous and homozygous SCA34 rats developed skin lesions from birth and later showed signs of cerebellar dysfunction typical of the human disease19. Analysis of skin VLC-SFA showed that the homozygous KI tissue had only about 33% of total VLC-SFA compared to WT controls. These findings indicate that the neuro-ichthyotic pathology in this mutant SCA34 model is likely caused by decreased skin and neuronal VLC-FA levels, an effect of the ELOVL4 mutation. We hypothesize that tissue-specific factors determine which type of VLC-FA (saturated versus polyunsaturated) is made and that the skin and cerebellar pathological defects found in SCA34 patients result from effects of the mutant ELOVL4 enzyme on the wild type ELOVL4’s ability to synthesize VLC-FA. We propose two specific aims to test this hypothesis. Upon successful completion of the proposed experiments, we will answer unresolved questions of how the different mutant ELOVL4 proteins affect VLC-FA biosynthesis to cause neuro-ichthyotic disorders. We anticipate this will allow us to pursue experimental treatment options in future studies which could progress rapidly into human clinical trials for treating some of the human mutant ELOVL4 disorders.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$1,612 )
2023	2020	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	2/2/2023	NON-COMPETING CONTINUATION	-$1,612
														Subtotal = -$1,612

Issue Date FY: 2022 ( Subtotal = -$330 )
2022	2020	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY STE 530	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	12/4/2021	NON-COMPETING CONTINUATION	-$330
														Subtotal = -$330

Issue Date FY: 2020 ( Subtotal = $159,500 )
2020	2020	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY STE 530	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	7/28/2020	NON-COMPETING CONTINUATION	$159,500
														Subtotal = $159,500

Issue Date FY: 2019 ( Subtotal = $191,400 )
2019	2019	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY STE 530	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	1	8/21/2019	NEW	$0
2019	2019	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY STE 530	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	7/28/2019	NEW	$191,400
														Subtotal = $191,400

Grand Total All Awards = $348,958

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Defining the Mechanism of Altered Very Long Chain Fatty Acid Metabolism in Neuro-Ichthyotic Disorders.

Award Number: R21AR076035

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer